流感疫苗接种后及呼吸道感染后疫苗安全监测相关结局在一般人群中的发生率:2022-2023年四项美国理赔数据库的描述性分析
该回顾性队列研究利用美国四个行政理赔数据源,估计2022年8月至2023年7月一般人群、流感疫苗接种者及SARS-CoV-2、呼吸道合胞病毒或流感感染就医者中30种安全结局的发生率。结果显示流感疫苗接种后发生率通常与一般人群相似或更低,而呼吸道感染后发生率通常更高且受基线差异混杂。
要点
- 流感疫苗接种后安全结局发生率通常与一般人群相似或更低。
- 呼吸道感染后安全结局发生率通常更高,但受基线差异混杂。
- 估计预期发生率时需考虑年龄和性别等混杂因素。
核心结论
- 本研究在COVID-19地方性流行期估计了30种与疫苗安全监测相关结局的发生率。
- 不同人口学组和队列间发生率存在差异,强调估计预期率时需考虑年龄和性别等混杂因素。
- 呼吸道感染后发生率升高为针对这些病毒的疫苗未来获益-风险评估提供了背景。
研究设计与样本
- 回顾性队列研究,使用美国四个行政理赔数据源:HealthVerity Closed Claims、Optum的de-identified Clinformatics® Data Mart、Humana和Medicare Fee-For-Service。
- 估计2022年8月1日至2023年7月31日期间五个队列中30种安全结局的发生率,覆盖五个器官系统。
- 五个队列为一般人群、流感疫苗接种者、以及因SARS-CoV-2、呼吸道合胞病毒或流感感染就医者。
- 分析整体进行,并按年龄和性别分层。
主要发现
- 流感疫苗接种后发生率通常与一般人群相似或更低,而呼吸道感染后发生率通常更高且受显著基线差异混杂。
- 在≥65岁成人中,心力衰竭、心房颤动、缺血性冠状动脉疾病和静脉血栓栓塞在所有队列中发生率最高。
- 在18-64岁成人中,呼吸道感染后癫痫、过敏反应和心血管结局最常见。
- 儿童中发生率最高的是≤5岁儿童的热性惊厥和<18岁儿童的癫痫;大多数其他结局罕见。
- 除自身免疫性疾病外,男性发生率与女性相似或更高。
临床怎么用
- 在COVID-19地方性流行期,可为疫苗安全监测中常见评估结局提供背景发生率参考。
- 估计疫苗安全监测的预期发生率时,应考虑年龄和性别等混杂因素。
- 呼吸道感染后发生率升高可用于未来针对这些病毒的疫苗获益-风险评估的背景参照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era. METHODS: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-For-Service) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Analyses were conducted overall and stratified by age and sex in five cohorts: the general population, influenza vaccine recipients, and those with medically attended SARS-CoV-2, respiratory syncytial virus, or influenza infection. RESULTS: IRs following influenza vaccination were generally similar to or lower than those in the general population, whereas rates after respiratory infections were generally higher and confounded by marked baseline differences. Among adults ≥65 years, heart failure, atrial fibrillation, ischemic coronary artery disease, and venous thromboembolism had the highest IRs across cohorts. Among adults aged 18-64 years, seizure, anaphylaxis and cardiovascular outcomes were most frequent after respiratory infections. The highest IRs in children were febrile seizures in those ≤5 years and seizures in <18 years; most other outcomes were rare. IRs were similar to or higher in males than females, except for autoimmune disorders. CONCLUSION: This study estimated IRs for 30 safety outcomes relevant to vaccine safety monitoring in a COVID-19 endemic period. Variation across demographic groups and cohorts underscores the importance of accounting for confounders including age and sex when estimating expected rates. Elevated IRs after respiratory infections provide context for future benefit-risk assessments for vaccines targeting these viruses before more rigorous adjusted analyses become available.
引用
- Bush C, Desai S, Wang H, et al. Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Vaccine. 2026. PMID: 42296834. doi:10.1016/j.vaccine.2026.128821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。